Radical new cell therapy aims to reset immune system in devastating lupus cases
NCT ID NCT06984341
Summary
This early-stage trial is testing a new type of cell therapy called P-CD19CD20-ALLO1 in people with severe lupus that hasn't responded to multiple treatments. Researchers will give 162 participants modified immune cells designed to target and remove the faulty B-cells that drive lupus inflammation. The main goals are to see if the treatment is safe and whether it can put lupus into remission without needing ongoing medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham: The Kirklin Clinic
RECRUITINGBirmingham, Alabama, 35233, United States
Conditions
Explore the condition pages connected to this study.